本研究的目的是评估 Desertliving肉苁蓉调节 PI3K/AKT 信号通路治疗去卵巢大鼠高脂性骨质疏松症的机制。我们将无特定病原体 (SPF) 大鼠随机分为五组 (n = 10)每组）。正常对照组给予标准饮食,模型组、阿托伐他汀组、己烯雌酚组、治疗组给予高脂饮食。四周后，进行双侧卵巢切除术，随后进行药物干预。治疗六周后，对相关指标进行对比分析。与正常对照组相比，模型组大鼠骨小梁形态模糊，骨细胞紊乱，骨特异性碱性磷酸酶（BALP）、骨Gla蛋白水平明显升高。 (BGP)、总胆固醇 (TC)、肿瘤坏死因子-α (TNF-α) 和 NF-κB 配体受体激活剂 (RANKL)。此外，模型组显示股骨中的极限负荷、骨折负荷、雌二醇 (E2)、骨矿物质密度 (BMD)、骨保护素 (OPG)、磷酸肌醇 3-激酶 (PI3K) 和蛋白激酶 B (Akt) 水平显着降低。组织。与正常对照组相比，阿托伐他汀组的 TC 和 TNF-α 水平较高。相反，治疗组表现出小梁形态增强、结构更致密、骨髓腔更小，并且 BALP、BGP、TC、TNF-α 和 RANKL 水平降低。此外，与模型组相比，治疗组骨组织中的E2、BMD、OPG、PI3K和Akt水平较高。治疗组的 TC 和 TNF-α 水平也低于阿托伐他汀组。生物力学分析表明，与模型组相比，服用 Desertliving 肉苁蓉后，治疗组体重减轻，股骨极限负荷和骨折负荷增加，骨结构更致密，骨髓腔更小，骨膜排列改变。我们的研究表明， Desertliving 肉苁蓉在预防和治疗大鼠绝经后高脂血症性骨质疏松症方面显示出显着功效。© 2024。作者。

To aim of this study is to assess the mechanism through which Desertliving Cistanche modulates the PI3K/AKT signaling pathway in the treatment of hyperlipidemic osteoporosis in ovariectomized rats.We randomly assigned specific-pathogen-free (SPF) rats into five groups (n = 10 per group). The normal control group received a standard diet, while the model group, atorvastatin group, diethylstilbestrol group, and treatment group were fed a high-fat diet. Four weeks later, bilateral ovariectomies were conducted, followed by drug interventions. After six weeks of treatment, relevant indicators were compared and analyzed.Compared to the normal control group, rats in the model group exhibited blurred trabecular morphology, disorganized osteocytes, significantly elevated levels of bone-specific alkaline phosphatase (BALP), bone Gla-protein (BGP), total cholesterol (TC), tumor necrosis factor-α (TNF-α), and receptor activator of NF-κB ligand (RANKL). Also, the model group revealed significantly reduced levels of ultimate load, fracture load, estradiol (E2), bone mineral density (BMD), osteoprotegerin (OPG), and phosphoinositide 3-kinase (PI3K) and protein kinase B (Akt) in femoral tissue. The atorvastatin group presented with higher TC and TNF-α levels compared to the normal control group. Conversely, the treatment group demonstrated enhanced trabecular morphology, denser structure, smaller bone marrow cavities, and reduced BALP, BGP, TC, TNF-α, and RANKL levels. Furthermore, the treatment group exhibited higher levels of E2, BMD, OPG, and PI3K and Akt in bone tissue compared to the model group. The treatment group also had lower TC and TNF-α levels than the atorvastatin group. Biomechanical analysis indicated that after administration of Desertliving Cistanche, the treatment group had reduced body mass, increased ultimate and fracture load of the femur, denser bone structure, smaller bone marrow cavities, and altered periosteal arrangement compared to the model group.Our study revealed that Desertliving Cistanche demonstrated significant efficacy in preventing and treating postmenopausal hyperlipidemic osteoporosis in rats.© 2024. The Author(s).